One lung cancer drug receives NHS England approval, while another is rejected
A targeted drug has been accepted for routine use on the NHS in England for some adults with untreated, advanced […]
HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical […] DUBLIN–(BUSINESS WIRE)–Dec. 27, 2018– Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved […]Approval
Moleculin Files with FDA for Expedited Approval Pathway for Annamycin
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns